题名 | Liquiritin reduces chondrocyte apoptosis through P53/PUMA signaling pathway to alleviate osteoarthritis |
作者 | |
发表日期 | 2024-04-15 |
发表期刊 | Life sciences 影响因子和分区 |
语种 | 英语 |
原始文献类型 | Journal Article |
关键词 | Apoptosis Liquiritin Osteoarthritis P53/PUMA |
其他关键词 | KNEE OSTEOARTHRITIS ; BH3-ONLY PROTEINS ; CELL-DEATH ; ALPHA ; PUMA |
摘要 | The main pathological features of osteoarthritis (OA) include the degeneration of articular cartilage and a decrease in matrix synthesis. Chondrocytes, which contribute to matrix synthesis, play a crucial role in the development of OA. Liquiritin, an effective ingredient extracted from Glycyrrhiza uralensis Fisch., has been used for over 1000 years to treat OA. This study aims to investigate the impact of liquiritin on OA and its underlying mechanism., Gait and hot plate tests assessed mouse behavior, while Micro-CT and ABH/OG staining observed joint morphological changes. The TUNEL kit detected chondrocyte apoptosis. Western blot and immunofluorescence techniques determined the expression levels of cartilage metabolism markers COL2 and MMP13, as well as apoptosis markers caspase3, bcl2, P53, and PUMA. KEGG analysis and molecular docking technology were used to verify the relationship between liquiritin and P53., Liquiritin alleviated pain sensitivity and improved gait impairment in OA mice. Additionally, we found that liquiritin could increase COL2 levels and decrease MMP13 levels both in vivo and in vitro. Importantly, liquiritin reduced chondrocyte apoptosis induced by OA, through decreased expression of caspase3 expression and increased expression of bcl2 expression. Molecular docking revealed a strong binding affinity between liquiritin and P53. Both in vivo and in vitro studies demonstrated that liquiritin suppressed the expression of P53 and PUMA in cartilage., This indicated that liquiritin may alleviate OA progression by inhibiting the P53/PUMA signaling pathway, suggesting that liquiritin is a potential strategy for the treatment of OA. |
资助项目 | Natural Science Foundation of Zhejiang Province[LY22H270005,LR23H270001];Chinese medicine scientific research projects[2022FSYYZY31];State Administration of Traditional Chinese Medicine of Zhejiang Province[2024ZL799,2024ZL052];Natural Science Foundation of China[82274550,82074457,82274280,82274549];Natural Science Foundation of Zhejiang Province[LY22H270005,LR23H270001];Natural Science Foundation of China[82274550,82274280,82104891,82274549]; |
出版者 | PERGAMON-ELSEVIER SCIENCE LTD |
ISSN | 0024-3205 |
EISSN | 1879-0631 |
卷号 | 343 |
DOI | 10.1016/j.lfs.2024.122536 |
页数 | 11 |
WOS类目 | Medicine, Research & Experimental ; Pharmacology & Pharmacy |
WOS研究方向 | Research & Experimental Medicine ; Pharmacology & Pharmacy |
WOS记录号 | WOS:001207053300001 |
收录类别 | PUBMED ; SCOPUS ; SCIE |
在线发表日期 | 2024-03 |
URL | 查看原文 |
PubMed ID | 3842317 |
SCOPUSEID | 2-s2.0-85187326863 |
通讯作者地址 | [Zhang, Chunchun]Institute of Orthopedics and Traumatology,The First Affiliated Hospital of Zhejiang Chinese Medical University (Zhejiang Provincial Hospital of Chinese Medicine),Hangzhou,China |
Scopus学科分类 | Biochemistry, Genetics and Molecular Biology (all);Pharmacology, Toxicology and Pharmaceutics (all) |
引用统计 | |
文献类型 | 期刊论文 |
条目标识符 | https://kms.wmu.edu.cn/handle/3ETUA0LF/210173 |
专题 | 附属第一医院 其他_附属萧山医院(杭州市萧山区第一人民医院) |
通讯作者 | Zhang, Chunchun |
作者单位 | 1.Institute of Orthopedics and Traumatology,The First Affiliated Hospital of Zhejiang Chinese Medical University (Zhejiang Provincial Hospital of Chinese Medicine),Hangzhou,China; 2.College of Pharmaceutical Sciences,Zhejiang Chinese Medical University,Hangzhou,China; 3.The First College of Clinical Medicine,Zhejiang Chinese Medical University,Hangzhou,China; 4.The First People's Hospital of Xiaoshan District,Xiaoshan Affiliated Hospital of Wenzhou Medical University,Hangzhou,China; 5.Department of the Orthopedic Surgery,the Second Affiliated Hospital of Zhejiang Chinese Medical University,Hangzhou,China; 6.Wenzhou Hospital of Integrated Traditional Chinese and Western Medicine,Wenzhou,China |
推荐引用方式 GB/T 7714 | Qiu, Min,Cheng, Liangyan,Xu, Jianbo,et al. Liquiritin reduces chondrocyte apoptosis through P53/PUMA signaling pathway to alleviate osteoarthritis[J]. Life sciences,2024,343. |
APA | Qiu, Min., Cheng, Liangyan., Xu, Jianbo., Jin, Minwei., Yuan, Wenhua., ... & Wang, Pinger. (2024). Liquiritin reduces chondrocyte apoptosis through P53/PUMA signaling pathway to alleviate osteoarthritis. Life sciences, 343. |
MLA | Qiu, Min,et al."Liquiritin reduces chondrocyte apoptosis through P53/PUMA signaling pathway to alleviate osteoarthritis".Life sciences 343(2024). |
条目包含的文件 | 条目无相关文件。 |
除非特别说明,本系统中所有内容都受版权保护,并保留所有权利。
修改评论